Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Marathon pauses...

    Marathon pauses Duchenne drug launch amid price outcry

    Written by supriya kashyap kashyap Published On 2017-02-14T12:38:32+05:30  |  Updated On 14 Feb 2017 12:38 PM IST
    Marathon pauses Duchenne drug launch amid price outcry

    Marathon Pharmaceuticals LLC said it was "pausing" the launch of its Duchenne muscular dystrophy drug after U.S. lawmakers questioned why the company priced it at $89,000 a year when patients had been able to import it for as little as $1,000.


    In a statement posted on the patient advocacy website Cure Duchenne, Marathon's chief executive, Jeffrey Aronin, said the company was pausing the launch amid "concerns about how the pricing and reimbursement details will affect individual patients and caregivers."


    The company said it would maintain its "expanded access program" under which 800 patients currently receive the drug for nothing. It said patients currently importing the drug from overseas would continue to be able to do so.


    The furore is the latest in a series related to U.S. drug prices, including Mylan NV's emergency EpiPen allergy treatment, that have drawn the ire of patients and lawmakers of all political stripes.


    Marathon's drug, Emflaza, known generically as deflazacort, is a steroid, one of a class of drugs commonly used to treat Duchenne's that patients could import for personal use because it was not available in the United States. Last week it won U.S. approval, in theory closing off that option.


    Earlier on Monday independent Senator Bernie Sanders of Vermont and Democratic congressman Elijah Cummings of Maryland, called on privately held Marathon to justify the price of the drug by documenting the cost involved in bringing it to market.


    Marathon, the lawmakers wrote in a letter to Aronin, did not after all develop the product, which has been around for decades. The company acquired rights to two clinical trials that had already been completed. And it conducted further toxicology and other tests to bring it through the U.S. regulatory process.


    Marathon argues that the studies it conducted had value in determining proper dosing, potential side effects and drug-to-drug interactions, allowing physicians to prescribe "with confidence."


    In a separate statement, Marathon said it appreciated the opportunity to discuss "the value of an FDA approval of a medicine" with Sanders and Cummings "and futhering our shared goal that every patient who needs this drug receives it."


    U.S. President Donald Trump has said he wants to lower drug prices and increase competition though he has not spelled out how.


    The Food and Drug Administration approved Emflaza under its "orphan" drug program that provides incentives to drug makers to develop treatments for diseases with small patient populations. The incentives include seven years of market exclusivity. Duchenne's, a devastating muscle-wasting disease, affects some 15,000 patients in the United States, mostly young boys.


    "Marathon will have a monopoly on deflazacort for years to come, preventing less expensive generic competitors from entering the market, despite the fact that this drug is already available in generic form in other countries," Sanders and Cummings wrote.

    DuchenneDuchenne drugDuchenne muscular dystrophyEmflazaEpiPenJeffrey AroninMarathonMylansteroids
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    supriya kashyap kashyap
    supriya kashyap kashyap
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok